VivoSim Labs Inc. Common Stock (VIVS)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the business. VivoSim Labs sells drug-safety testing using 3D human liver and intestinal tissue models, with only 15 employees. The reported record is grim. In fiscal Q1 2027, the quarter ended 2026-06-30, revenue was $18,000 and net income was -$1.3 million, or -$0.25 per diluted share. Fiscal Q2 2026, the quarter ended 2025-09-30, had revenue of $28,000 and a net loss of $2.5 million. Fiscal Q3 2026, the quarter ended 2025-12-31, had revenue of $26,000 and a net loss of $2.7 million. Fiscal Q1 2026, the quarter ended 2025-06-30, had revenue of $37,000 and a net loss of $2.8 million. Full fiscal 2026, the year ended 2026-03-31, revenue was $131,000 and net loss was $13.8 million, versus fiscal 2025, the year ended 2025-03-31, revenue of $144,000 and net loss of $2.5 million. That is not a durable enterprise; it is a cash-burning experiment. I see no moat. A company with revenue in the tens of thousands has no pricing power or scale I can rely on. The Lynch category is none, because of losses in each of the last four years, so it fails a basic profitability test. At the 2026-10-13 close of $0.17, the market cap was about $2.5 million. FairStock's P/B is 0.76 and P/E is -0.04. A discount to book can matter, but book value shrinks with every loss. FairStock's trailing FCF yield was -401%, based on trailing free cash flow of -$10.1 million. FairStock's Piotroski score was 1/9 and Altman Z was -131.74. FairStock's ROE was -343.10% and ROCE -89.50%. Debt-to-equity of 0.18 is modest, but that is little comfort when the business cannot cover its costs. I would demand a much larger margin of safety, and I see none.

In plain English: VivoSim Labs tests drugs using small three-dimensional human tissue models of liver and intestine. The business is very small and losing money: in the quarter ended 2026-06-30, sales were $18,000 and it lost $1.3 million. At 17 cents a share, the stock trades below its accounting book value, but the heavy losses and negative cash flow make the cheap price look risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer